Mode of action of empagliflozin to prevent heart failure

20 May 2024

Identifying proteins and pathways that drive one drug’s mechanism of action can further the understanding of multiple diseases, and may point to new therapeutics. Olink describes the mode of action of empagliflozin in preventing heart failure, highlighting insights derived from completed clinical trial samples, such as the EMPEROR STUDY, a clinical trial using 1,134 patient samples in a continuous study at weeks 0, 12, and 52 using Olink Explore®.